一种用于治疗慢性肾脏病患者贫血的新兴疗法：达普司他的综述。
An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat.
机构信息
Lerin Drug Co. Inc., New York, NY, USA.
St. John's University, Jamaica, NY, USA.
出版信息
Adv Ther. 2018 Jan;35(1):5-11. doi: 10.1007/s12325-017-0655-z. Epub 2017 Dec 28.
Abstract
This article reviews an emerging therapeutic agent, which is currently in phase III development for the treatment of anemia secondary to chronic kidney disease, covering promising phase II results, drug characteristics, and the current phase III trials, which, if approved, may significantly impact the management of anemia in this patient population.
摘要
本文回顾了一种新兴的治疗药物，该药物目前正处于治疗慢性肾脏病相关贫血的 III 期开发阶段，涵盖了有前景的 II 期研究结果、药物特征以及当前的 III 期临床试验。如果获得批准，该药物可能会对该患者人群的贫血管理产生重大影响。
相似文献
1
An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat.一种用于治疗慢性肾脏病患者贫血的新兴疗法：达普司他的综述。
Adv Ther. 2018 Jan;35(1):5-11. doi: 10.1007/s12325-017-0655-z. Epub 2017 Dec 28.
2
A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.一项随机、29 天、剂量范围、评估达普司他疗效和安全性的研究，在每周三次给药方案下，评估达普司他在血液透析患者中的应用。
BMC Nephrol. 2019 Oct 16;20(1):372. doi: 10.1186/s12882-019-1547-z.
3
A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.达泊西汀对日本透析患者进行的为期24周的贫血纠正研究。 （注：原文中药物名称可能有误，推测正确药物名应为Daproxetine，翻译为达泊西汀；而文本中实际药物名Daprodustat常见中文名是达普司他，是一种促红细胞生成素受体激动剂，常用于治疗肾性贫血等，这里按照正确药物名达普司他给出译文）
达普司他对日本透析患者的24周贫血纠正研究。
Ther Apher Dial. 2020 Apr;24(2):108-114. doi: 10.1111/1744-9987.12962. Epub 2019 Aug 13.
4
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.达普司他用于治疗透析患者的贫血
N Engl J Med. 2021 Dec 16;385(25):2325-2335. doi: 10.1056/NEJMoa2113379. Epub 2021 Nov 5.
5
A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.慢性肾脏病患者贫血管理的新方法：罗沙司他综述
Adv Ther. 2017 Apr;34(4):848-853. doi: 10.1007/s12325-017-0508-9. Epub 2017 Mar 13.
6
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.新型缺氧诱导因子脯氨酰羟化酶抑制剂达普司他对日本血液透析患者贫血管理的影响
Am J Nephrol. 2017;45(2):127-135. doi: 10.1159/000454818. Epub 2016 Dec 16.
7
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.达普司他用于治疗未接受透析患者的贫血
N Engl J Med. 2021 Dec 16;385(25):2313-2324. doi: 10.1056/NEJMoa2113380. Epub 2021 Nov 5.
8
The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.比较非透析慢性肾脏病患者肾性贫血治疗中vadadustat 和 daprodustat 的剂量、成本和安全性。
Intern Med. 2024 Jul 1;63(13):1855-1861. doi: 10.2169/internalmedicine.2501-23. Epub 2023 Nov 6.
9
Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.达普司他在日本腹膜透析患者中的疗效和安全性。
Ther Apher Dial. 2021 Dec;25(6):979-987. doi: 10.1111/1744-9987.13686. Epub 2021 May 25.
10
Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.达泊西汀对慢性肾脏病患者贫血的影响：一项荟萃分析。
Int Urol Nephrol. 2018 Dec;50(12):2201-2206. doi: 10.1007/s11255-018-1940-8. Epub 2018 Aug 2.
引用本文的文献
1
The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review.缺氧诱导因子脯氨酰羟化酶抑制剂达普司他在依赖透析和非依赖透析的慢性肾脏病贫血患者中的作用及临床意义：综述
Front Nephrol. 2024 Dec 23;4:1511596. doi: 10.3389/fneph.2024.1511596. eCollection 2024.
2
Adipocyte deletion of the oxygen-sensor PHD2 sustains elevated energy expenditure at thermoneutrality.脂肪细胞中氧传感器 PHD2 的缺失可维持其在热中性温度下的高能量消耗。
Nat Commun. 2024 Aug 29;15(1):7483. doi: 10.1038/s41467-024-51718-7.
3
Transforming the management of chronic kidney disease-associated anemia using daprodustat.使用达普司他改变慢性肾脏病相关性贫血的管理。
Ann Med Surg (Lond). 2024 May 20;86(7):3824-3826. doi: 10.1097/MS9.0000000000002207. eCollection 2024 Jul.
4
Chemistry, Analysis, and Biological Aspects of Daprodustat, A New Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor: A Comprehensive Review.达普司他的化学、分析和生物学特性：一种新型缺氧诱导因子脯氨酰羟化酶抑制剂：全面综述。
Mini Rev Med Chem. 2024;24(20):1847-1855. doi: 10.2174/0113895575293447240424052516.
5
Quantitative systems pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease.用于模拟针对慢性肾脏病所致贫血的治疗方法的红细胞生成定量系统药理学模型。
Front Pharmacol. 2023 Dec 6;14:1274490. doi: 10.3389/fphar.2023.1274490. eCollection 2023.
6
An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients.缺氧诱导因子脯氨酰羟化酶抑制剂与促红细胞生成素刺激剂在治疗慢性肾脏病患者贫血方面的安全性和有效性概述
Cureus. 2023 Jul 17;15(7):e42045. doi: 10.7759/cureus.42045. eCollection 2023 Jul.
7
Daprodustat: First Approval.达普司他：首次批准。
Drugs. 2020 Sep;80(14):1491-1497. doi: 10.1007/s40265-020-01384-y.
8
Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome.常染色体显性遗传高免疫球蛋白 E 综合征中的血管生成和细胞外基质代谢受损。
J Clin Invest. 2020 Aug 3;130(8):4167-4181. doi: 10.1172/JCI135490.
9
Marginal zone lymphoma causing accelerated progression of chronic kidney disease.边缘区淋巴瘤导致慢性肾脏病加速进展。
BMJ Case Rep. 2019 Nov 10;12(11):e230270. doi: 10.1136/bcr-2019-230270.
10
Targeting HIF-1 to Prevent Renal Ischemia-Reperfusion Injury: Does It Work?靶向缺氧诱导因子-1预防肾缺血再灌注损伤：是否可行？
Int J Cell Biol. 2018 Nov 25;2018:9852791. doi: 10.1155/2018/9852791. eCollection 2018.
本文引用的文献
1
A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.慢性肾脏病患者贫血管理的新方法：罗沙司他综述
Adv Ther. 2017 Apr;34(4):848-853. doi: 10.1007/s12325-017-0508-9. Epub 2017 Mar 13.
2
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.缺氧诱导因子脯氨酰羟化酶抑制剂：治疗慢性肾脏病患者贫血的一种新方法。
Am J Kidney Dis. 2017 Jun;69(6):815-826. doi: 10.1053/j.ajkd.2016.12.011. Epub 2017 Feb 24.
3
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.新型缺氧诱导因子脯氨酰羟化酶抑制剂达普司他对日本血液透析患者贫血管理的影响
Am J Nephrol. 2017;45(2):127-135. doi: 10.1159/000454818. Epub 2016 Dec 16.
4
Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863.食物和吉非贝齐对新型脯氨酰羟化酶抑制剂 GSK1278863 药代动力学的影响。
Clin Pharmacol Drug Dev. 2014 Mar;3(2):109-17. doi: 10.1002/cpdd.83. Epub 2013 Oct 22.
5
A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.一种新型缺氧诱导因子脯氨酰羟化酶抑制剂（GSK1278863）治疗 CKD 相关贫血的 28 天、2A 期随机试验。
Am J Kidney Dis. 2016 Jun;67(6):861-71. doi: 10.1053/j.ajkd.2015.11.021. Epub 2016 Jan 27.
6
Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects.新型低氧诱导因子脯氨酰羟化酶抑制剂GSK1278863单剂量口服给药在健康日本人和高加索人中的药代动力学、药效学及安全性研究
Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8. doi: 10.1016/j.dmpk.2015.08.004. Epub 2015 Aug 28.
7
Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.口服低氧诱导因子脯氨酰羟化酶抑制剂GSK1278863治疗贫血的四周研究
J Am Soc Nephrol. 2016 Apr;27(4):1234-44. doi: 10.1681/ASN.2014111139. Epub 2015 Oct 22.
8
Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease.用一种新型低氧诱导因子脯氨酰羟化酶抑制剂（GSK1278863）进行短期治疗，未能改善间歇性跛行受限的外周动脉疾病患者的运动能力指标。
Vasc Med. 2014 Dec;19(6):473-82. doi: 10.1177/1358863X14557151. Epub 2014 Nov 6.
9
Prevalence of anemia in chronic kidney disease in the United States.美国慢性肾脏病患者贫血的患病率
PLoS One. 2014 Jan 2;9(1):e84943. doi: 10.1371/journal.pone.0084943. eCollection 2014.
10
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.羧基麦芽糖铁用于缺铁性贫血合并肾功能损害患者：REPAIR-IDA试验
Nephrol Dial Transplant. 2014 Apr;29(4):833-42. doi: 10.1093/ndt/gft251. Epub 2013 Aug 20.
Zotero 插件